Genewel Genewel acquired manufacturing license for ‘Pain Reducing Drug Delivery Kit’ from the Ministry of Food and Drug Safety

Genewel has obtained a manufacturing license from the Ministry of Food and Drug Safety for a new concept pain-reducing drug delivery kit. Until now, narcotic analgesics have been administered directly or injected through a pain control device to reduce pain in the incision site after surgery, but there has been controversy over drug overdose and side effects.
The pain-reducing drug delivery kit developed by Genewel is a new concept medical device that is mixed with a local anesthetic and applied directly before sealing the surgical incision so that the drug is continuously released for 72 hours. It is expected to change the paradigm of pain management after surgery in the future.
The product successfully completed domestic clinical trials in June 2019 and its efficacy and safety have been proven. In addition, in January 2020, in recognition of its technological excellence, it obtained a domestic patent and has applied for a patent in nine overseas countries including Europe and the United States. Genewel is preparing to enter the overseas market as well as launch in Korea, starting with this approval from the Ministry of Food and Drug Safety.